Market Overview:
The global soliris drug market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of rare diseases, rising demand for innovative therapies, and growing investments by pharmaceutical companies in R&D activities. The plasma exchange segment is expected to account for the largest share of the global soliris drug market in 2018. This segment is also projected to grow at a higher CAGR than other segments during the forecast period. The high growth rate of this segment can be attributed to increasing awareness about plasma exchange as a treatment option for various rare diseases and its growing adoption among patients worldwide. On the basis of application, PNH is expected to account for the largest share of the global soliris drug market in 2018. This segment is also projected grow at a higher CAGR than other segments duringthe forecast period owingtoits high prevalence and unmet medical needs across different geographies.
Product Definition:
Soliris is an intravenous drug used to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and aHUS. It is also indicated for the treatment of adult patients with atypical hemolytic uremic syndrome (aHUS) who are intolerant to or have failed therapy with other eculizumab products.
Plasma Exchange:
Plasma exchange is a medical procedure wherein the blood of a patient is separated and replaced with healthy donor blood. This process helps in removing harmful antibodies from the body as well as improves the functioning of various organs. Plasma exchange also helps in boosting up the immune system by increasing white blood cells, red blood cells and platelets count which further help to fight against diseases such as anemia, arthritis, asthma etc.
Plasma Infusion:
Plasma infusion is a procedure wherein the blood of a patient is transferred to another container for re-infusion at a later time. It's an advanced form of hemodialysis that helps in treating patients with end-stage renal disease and acute kidney injury. Soliris (eculizumab)is the first and only drug approved by Merck & Co., Inc. for treatment against ESRD (End-stage Renal Disease).
Application Insights:
The other application segment includes the soliris use in patients with PNH and aHUS. The growing prevalence of these diseases coupled with increasing R&D initiatives by various companies is expected to drive the global market for soliris over the forecast period.
Based on application, the global market has been further segmented into porphyria cutanea tarda (PCT), aHUS, other PN/rheumatic disease and others.
Regional Analysis:
Europe accounted for the largest share of global revenue in 2017. The presence of key players, favorable government initiatives, and high prevalence of rare diseases are some factors responsible for its large share. In addition, increasing R&D activities to develop new therapies is expected to fuel the region’s growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising healthcare expenditure and improving economic conditions in emerging countries such as China & India & South Korea etcetera (CIS). Moreover, growing awareness about advanced treatment options among patients will drive this market further. Increasing number of product launches by companies operating in this region also contributes toward market development (for instance; Novartis AG launched a new formulation Soliris at 50 mg dose that is film-coated and thus easier to swallow).
Growth Factors:
- Increasing incidence of rare diseases: The global prevalence of rare diseases is estimated to be around 350 million people. This number is expected to grow as the population ages and new technologies enable earlier diagnosis of rare diseases. There are approximately 7,000 known rare diseases, and each one affects fewer than 1 in 2,000 people.2
- Growing demand for orphan drugs: The market for orphan drugs is growing rapidly as pharmaceutical companies focus on developing treatments for rare diseases that often lack effective therapies.3 In the United States alone, the orphan drug market was worth more than billion in 2016 and is projected to reach billion by 2022.4
- Advances in gene therapy: Gene therapy offers a potential cure for many genetic disorders by replacing or repairing defective genes using engineered viruses or cells.5 This technology is still in its early stages of development, but there are already several approved gene therapies available on the market and many more in clinical trials.6 As this technology advances, it could provide a much-needed treatment option for patients with serious genetic disorders like sickle cell anemia and cystic fibrosis .7
Scope Of The Report
Report Attributes
Report Details
Report Title
Soliris Drug Market Research Report
By Type
Plasma Exchange, Plasma Infusion
By Application
PNH, aHUS, Other
By Companies
Alexion, Alexion
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
152
Number of Tables & Figures
107
Customization Available
Yes, the report can be customized as per your need.
Global Soliris Drug Market Report Segments:
The global Soliris Drug market is segmented on the basis of:
Types
Plasma Exchange, Plasma Infusion
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
PNH, aHUS, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Alexion
- Alexion
Highlights of The Soliris Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Plasma Exchange
- Plasma Infusion
- By Application:
- PNH
- aHUS
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Soliris Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Soliris is a drug that treats rare diseases. It is a new type of medicine called an RNAi therapy. Soliris works by stopping the growth of cancer cells in the body.
Some of the key players operating in the soliris drug market are Alexion, Alexion.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Soliris Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Soliris Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Soliris Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Soliris Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Soliris Drug Market Size & Forecast, 2020-2028
4.5.1 Soliris Drug Market Size and Y-o-Y Growth
4.5.2 Soliris Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Plasma Exchange
5.2.2 Plasma Infusion
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 PNH
6.2.2 aHUS
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Soliris Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Soliris Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Plasma Exchange
9.6.2 Plasma Infusion
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 PNH
9.10.2 aHUS
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Plasma Exchange
10.6.2 Plasma Infusion
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 PNH
10.10.2 aHUS
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Plasma Exchange
11.6.2 Plasma Infusion
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 PNH
11.10.2 aHUS
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Plasma Exchange
12.6.2 Plasma Infusion
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 PNH
12.10.2 aHUS
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Plasma Exchange
13.6.2 Plasma Infusion
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 PNH
13.10.2 aHUS
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Soliris Drug Market: Competitive Dashboard
14.2 Global Soliris Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Alexion
14.3.2 Alexion
